RxDoctor Payments Data

Maria Smith, MD

Internal Medicine · Flint, MINPI 1285890517

Payments from drug & device makers

$987in general payments, 2019–2025

Across 53 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$284
  • Amgen$135
  • Pfizer$124
  • Corcept Therapeutics$77
  • Lilly USA, LLC$61
  • AbbVie$57
  • plus $249 from 10 others

What the payments were for

  • Food & beverage$987100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$987 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$138,390
Medicare patients
304
Services billed
1,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide165$287,554
EliquisApixaban190$209,693
JardianceEmpagliflozin62$87,130
MounjaroTirzepatide55$80,220
TrulicityDulaglutide31$38,973
XareltoRivaroxaban22$34,104
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$18,887
PaxlovidNirmatrelvir/Ritonavir30$16,164
Tresiba Flextouch U-100Insulin Degludec20$15,926
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$10,396
Lantus SolostarInsulin Glargine,hum.Rec.Anlog58$10,213
BrilintaTicagrelor13$9,811
Atorvastatin Calcium573$8,847
Levothyroxine Sodium598$7,116
Rosuvastatin Calcium256$5,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$284$287,554165 claims
PfizerEliquis, Paxlovid$124$225,857220 claims
Lilly USA, LLCMounjaro, Trulicity$61$119,19386 claims
Boehringer IngelheimJardiance$21$87,13062 claims
Johnson & JohnsonXarelto$21$34,10422 claims
GSKTrelegy Ellipta$18$18,88730 claims
AstraZenecaBrilinta$16$9,81113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →